Patent application number | Description | Published |
20110028541 | LUBIPROSTONE CRYSTAL, THE USE AND THE METHOD FOR THE PREPARATION THEREOF - The present invention relates to a lubiprostone crystal, the method for the preparation thereof, and a pharmaceutical composition or kit comprising the same, as well as the use of said crystal in the preparation of a medicament for the treatment of gastrointestinal tract diseases, especially constipation. The X-ray powder diffraction pattern of said crystal comprises characteristic peaks measured at the following 2θ reflection angles: 14.6±0.2°, 17.0±0.2° and 19.6±0.2°. As compared to amorphous lubiprostone, the crystal of the present invention has the advantages of relative high purity, stable properties and easy-for-storage and use. | 02-03-2011 |
20120270946 | CRYSTALLINE FORM OF BIMATOPROST, PREPARATION METHOD AND USE THEREOF - The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2θ are 3.2+0.2°, 5.5+0.2°, 11.4+0.2°, 16.7+0.2°, 17.6+0.2°, 19.9+0.2°, 20.8±02° and 22.8+0.2° in the X-ray powder diffraction pattern of the crystalline form A. | 10-25-2012 |
20130030150 | Purification Method of Azacyclohexapeptide or Its Salt - A purification method of the compound represented by formula 1 is provided, which includes the following steps: (1) loading crude compound 1 on macroporous adsorbent resin, (2) washing the macroporous adsorbent resin with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water, (3) eluting with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water. The purified compound represented by formula 1 is obtained. | 01-31-2013 |
20130190404 | CRYSTALS OF CARBOPROST TROMETHAMINE AND THE PREPARATION METHOD AS WELL AS THE USES THEREOF - Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has characteristic peaks in the X-ray diffraction pattern at the following 2θ angles: 6.6±0.2°, 9.9±0.2°, 18.5±0.2° and 20.1±0.2°. Furthermore, also disclosed are preparation method and the use of the crystal. | 07-25-2013 |
20130225482 | CASPOFUNGIN ANALOG, AND PREPARATION METHOD AND USES THEREOF - Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3. | 08-29-2013 |
20130231457 | PREPARATION METHOD FOR CASPOFUNGIN - Disclosed is a preparation method for caspofungin, comprising the steps: (a) a compound as represented in Formula 2 and a strong leaving group 5 are mixed to obtain a compound as represented in Formula 3; (b) the compound as represented in Formula 3 and ethylenediamine are mixed to obtain a compound as represented in Formula 4; and, (c) the compound as represented in Formula 4 is mixed with a hydroxyl protection agent, and then a borane complex is mixed in to obtain a compound as represented in Formula 1. | 09-05-2013 |
20130296229 | CASPOFUNGIN ANALOG AND APPLICATIONS THEREOF - Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R | 11-07-2013 |
20140114049 | PREPARATION METHOD OF MICAFUNGIN SODIUM - The method of the preparation of micafungin sodium comprises the step of mixing the weak base and the aqueous solution containing micafungin acid (the structure is illustrated by formula I) or the mixed aqueous solution containing the compound of formula I and organic solvent in order to obtain the sodium salt of micafungin (the structure is illustrated by formula II). | 04-24-2014 |
20140128315 | CASPOFUNGIN OR SALTS THEREOF WITH HIGH PURITY, AS WELL AS PREPARATION METHOD AND USE THEREOF - Disclosed are a high purity of caspofungin or salts thereof, and a preparation method thereof, and use thereof. Disclosed are a caspofungin or salts thereof with low solvent residue and hyposaline, and a preparation process comprising: dissolving a crude product of caspofungin or slats thereof into a system of water and acetic acid, them mixing with a first organic solvent ethyl alcohol, subsequently mixing with a second organic solvent ethyl acetate, then being subject to filtration and drying together with water, to obtain caspofungin or salts thereof with high stability, low solvent residue and hyposaline. | 05-08-2014 |
20150057234 | HYDRATE OF CYCLOPEPTIDE COMPOUND AS WELL AS PREPARATION METHOD AND USE THEREOF - Disclosed is a hydrate of a compound as shown in Formula I. In formula I, R represents H or a cation capable of forming a pharmaceutically acceptable salt. The mass percentage of water in the hydrate is more than 8%. The hydrate has good stability. Moreover, disclosed are a preparation method and a use thereof. | 02-26-2015 |
20150065417 | HIGH PURITY CYCLOPEPTIDE COMPOUND AS WELL AS PREPARATION METHOD AND USE THEREOF - Disclosed is a high purity cyclopeptide compound, the chemical structure of which is represented by formula (I). R represents H or a cation capable of forming a pharmaceutically acceptable salt, the purity being greater than or equal to 99.0%. Further disclosed are preparation method and use of the high purity cyclopeptide compound. | 03-05-2015 |